MaaT Pharma (FR:MAAT)
:MAAT
Want to see FR:MAAT full AI Analyst Report?
Top Page
MaaT Pharma
(MAAT)
Select Model
Select Model
Rating:42Neutral
Price Target:
€3.00
▼(-45.55% Downside)
Action:Reiterated
Date:05/27/26
The score is weighed down primarily by weak financial quality (large losses, ongoing cash burn, and a weakened balance sheet with higher debt and sharply lower equity) and very bearish technicals (price far below moving averages with negative momentum). Revenue growth provides some support, but valuation signals are limited due to negative earnings and no dividend data.
Positive Factors
Revenue Growth Trend
Sustained double‑digit revenue growth from €0 in 2020 to ~€4.5M in 2025 indicates early commercial traction and expanding market adoption. Over 2–6 months this trend underpins durable top‑line momentum and the potential to leverage fixed R&D and commercial costs as scale increases.
Negative Factors
Heavy Cash Burn & Negative FCF
Persistently negative operating cash flow and materially negative free cash flow indicate ongoing dependence on external financing to fund operations and trials. Over a medium horizon this raises dilution and runway risk, constraining strategic options until sustainable cash generation or material financing occurs.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth Trend
Sustained double‑digit revenue growth from €0 in 2020 to ~€4.5M in 2025 indicates early commercial traction and expanding market adoption. Over 2–6 months this trend underpins durable top‑line momentum and the potential to leverage fixed R&D and commercial costs as scale increases.
Read all positive factors
MaaT Pharma (MAAT) vs. iShares MSCI France ETF (EWQ)
Market Cap
€53.83M
Dividend YieldN/A
Average Volume (3M)99.82K
Price to Earnings (P/E)―
Beta (1Y)-0.13
Revenue Growth40.67%
EPS Growth11.49%
CountryFR
Employees59
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.95
Shares Outstanding18,856,394
10 Day Avg. Volume94,708
30 Day Avg. Volume99,816
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)42.60
Price to Sales (P/S)16.94
P/FCF Ratio-4.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€18.00Price Target Upside226.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.81
Revenue Forecast (FY)€13.29M
MaaT Pharma Business Overview & Revenue Model
Company Description
MaaT Pharma SA operates as a clinical-stage biotechnology company, focused on the discovery and advancement of microbiome-based biotherapies, primarily for the treatment of solid cancer tumors. Its development pipeline features MaaT013, which has ...
How the Company Makes Money
null...
MaaT Pharma Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
18
Very Negative
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.52M | 3.22M | 2.23M | 1.43M | 972.00K |
| Gross Profit | 1.39M | 1.97M | 784.00K | 1.09M | 806.00K |
| EBITDA | -32.41M | -26.34M | -22.07M | -13.10M | -8.57M |
| Net Income | -31.06M | -28.90M | -19.72M | -13.71M | -9.02M |
Balance Sheet | |||||
| Total Assets | 44.55M | 38.50M | 42.93M | 44.73M | 49.42M |
| Cash, Cash Equivalents and Short-Term Investments | 24.87M | 20.22M | 24.31M | 35.31M | 43.30M |
| Total Debt | 17.44M | 15.96M | 14.07M | 11.36M | 5.81M |
| Total Liabilities | 42.75M | 28.16M | 22.46M | 17.91M | 9.56M |
| Stockholders Equity | 1.80M | 10.34M | 20.47M | 26.81M | 39.86M |
Cash Flow | |||||
| Free Cash Flow | -16.52M | -22.79M | -19.76M | -13.27M | -8.17M |
| Operating Cash Flow | -15.91M | -22.04M | -18.67M | -12.61M | -7.93M |
| Investing Cash Flow | -497.00K | -416.00K | -440.00K | -815.00K | -238.00K |
| Financing Cash Flow | 21.12M | 18.33M | 8.14M | 5.36M | 31.56M |
MaaT Pharma Technical Analysis
Negative
5.51
Price Trends
4.71
Negative
5.83
Negative
5.11
Negative
Market Momentum
-0.58
Negative
30.45
Neutral
48.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:MAAT, the sentiment is Negative. The current price of 5.51 is above the 20-day moving average (MA) of 2.87, above the 50-day MA of 4.71, and above the 200-day MA of 5.11, indicating a bearish trend. The MACD of -0.58 indicates Negative momentum. The RSI at 30.45 is Neutral, neither overbought nor oversold. The STOCH value of 48.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:MAAT.
MaaT Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | €151.00M | -2.97 | -658.91% | ― | -77.92% | 11.11% | |
48 Neutral | €208.49M | -3.19 | -634.16% | ― | 291.43% | 12.24% | |
46 Neutral | €1.53B | -60.16 | ― | ― | ― | ― | |
44 Neutral | €6.79B | -17.83 | ― | ― | ― | ― | |
43 Neutral | €193.11M | -4.62 | -30.75% | ― | 32.62% | -7.59% | |
42 Neutral | €53.83M | -1.55 | ― | ― | 40.67% | 11.49% |
* Healthcare Sector Average
FR:MAAT
MaaT Pharma
2.86
-2.23
-43.80%
FR:IPH
Innate Pharma SA
1.61
0.08
5.10%
FR:ABVX
Abivax SA
85.05
79.87
1541.89%
FR:NANO
Nanobiotix
30.32
26.56
706.38%
FR:TNG
Transgene
0.75
-0.12
-13.36%
FR:ALCLS
Cellectis SA
2.67
1.41
111.90%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.